文献速递系统性红斑狼疮

阿尼鲁单抗治疗系统性红斑狼疮患者中LLDAS与缓解的达成:TULIP及长期扩展随机对照试验结果

LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trials.
PubMed 文献 · Ann Rheum Dis · 2025-01-30

该事后分析纳入369例中重度SLE患者(阿尼鲁单抗257例、安慰剂112例),评估阿尼鲁单抗300mg每4周静脉给药对LLDAS和DORIS缓解的长期影响。治疗208周时,阿尼鲁单抗组36.9%达LLDAS vs 安慰剂组17.1%(OR 2.7,95%CI 1.3-5.5,P=.0081),DORIS为30.3% vs 18.3%(OR 1.9,95%CI 1.0-3.9,P=.0663)。作者认为LLDAS和DORIS是长期阿尼鲁单抗治疗可达且可持续的治疗目标。

要点

  • 治疗208周时阿尼鲁单抗组36.9%达LLDAS vs 安慰剂组17.1%(OR 2.7,95%CI 1.3-5.5,P=.0081)。
  • 治疗208周时DORIS缓解率阿尼鲁单抗组30.3% vs 安慰剂组18.3%(OR 1.9,95%CI 1.0-3.9,P=.0663)。
  • 首次达LLDAS和DORIS的时间均有利于阿尼鲁单抗组(HR 1.56和HR 1.50)。

核心结论

  • 长期阿尼鲁单抗治疗下,LLDAS和DORIS缓解是可达且可持续的治疗目标。

研究设计与样本

  • 事后分析纳入52周3期TULIP-1/TULIP-2试验中随机接受静脉阿尼鲁单抗300mg或安慰剂(每4周一次)的中重度SLE患者,并在3年长期扩展中继续相同治疗。
  • 分析共纳入369例患者(阿尼鲁单抗组257例,安慰剂组112例)。

主要发现

  • 治疗208周时,阿尼鲁单抗组36.9%达LLDAS vs 安慰剂组17.1%(OR 2.7,95%CI 1.3-5.5,P=.0081)。
  • 治疗208周时,阿尼鲁单抗组30.3%达DORIS vs 安慰剂组18.3%(OR 1.9,95%CI 1.0-3.9,P=.0663)。
  • 首次达LLDAS的时间有利于阿尼鲁单抗组(HR 1.56,95%CI 1.18-2.09,P=.0024)。
  • 首次达DORIS的时间有利于阿尼鲁单抗组(HR 1.50,95%CI 1.04-2.22,P=.0373)。
  • 阿尼鲁单抗组处于LLDAS和DORIS的累积时间均大于安慰剂组(P=.0004和P=.0032)。

关键数值与推荐

  • LLDAS和DORIS缓解与SLE患者损伤减少和死亡率降低等良好结局相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the long-term impact of anifrolumab versus placebo on lupus low disease activity state (LLDAS) and definition of remission in systemic lupus erythematosus (DORIS) attainment in patients with systemic lupus erythematosus (SLE). METHODS: This post hoc analysis included patients with moderate to severe SLE who were randomly assigned to receive intravenous anifrolumab 300 mg or placebo (once every 4 weeks) in the 52-week, phase 3 TULIP-1/TULIP-2 trials and continued with the same treatment in the 3-year long-term extension. LLDAS/DORIS rates over time were analysed using a stratified Cochran-Mantel-Haenszel approach and logistic regression. Time to first LLDAS/DORIS was estimated using Cox regression. Cumulative time and percentage of time in LLDAS/DORIS were assessed using an analysis of covariance. All P values are nominal. RESULTS: This analysis included 369 patients (anifrolumab n = 257, placebo n = 112). After 4 years of treatment (at Week 208), 36.9% of anifrolumab-treated patients versus 17.1% of placebo-treated patients were in LLDAS (odds ratio [OR], 2.7; 95% CI, 1.3-5.5; P = .0081); 30.3% versus 18.3% were in DORIS (OR, 1.9; 95% CI, 1.0-3.9; P = .0663). Time to first LLDAS and DORIS favoured anifrolumab versus placebo (LLDAS: hazard ratio, 1.56; 95% CI, 1.18-2.09; P = .0024; DORIS: hazard ratio, 1.50; 95% CI, 1.04-2.22; P = .0373). Cumulative time in LLDAS and DORIS was greater with anifrolumab than that with placebo (P = .0004 and P = .0032, respectively). CONCLUSIONS: LLDAS and DORIS remission, which are associated with favourable outcomes such as reduced damage and mortality in patients with SLE, are attainable and sustainable treatment targets with long-term anifrolumab treatment.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Morand EF, van Vollenhoven R, Furie RA, et al. LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trials. Ann Rheum Dis. 2025. PMID: 39948001. doi:10.1016/j.ard.2025.01.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。